329
Views
5
CrossRef citations to date
0
Altmetric
Letters

Pediatric hidradenitis suppurativa: epidemiology, disease presentation, and treatments

, ORCID Icon, ORCID Icon, , , ORCID Icon & show all
Pages 2391-2393 | Received 03 May 2021, Accepted 23 May 2021, Published online: 23 Mar 2022
 

Disclosure statement

J. L. H. is on the Board of Directors for the Hidradenitis Suppurativa Foundation and has served as an advisor for Novartis and a speaker for AbbVie. V. Y. S. is on the Board of the Directors for the Hidradenitis Suppurativa Foundation, and has served as an advisor, investigator and/or speaker for Sanofi Genzyme, Regeneron, AbbVie, Burt’s Bees, Dermira, Eli Lilly, Novartis, Pfizer, Galderma, Leo Pharma, SUN Pharma, Menlo Therapeutics, GpSkin, and Skin Actives Scientific. M. H. is an investigator for Amgen and Celgene. J. R. S., E. K. C., T. G., and T. S. report no conflicts of interest. There was no financial transaction for the preparation of this manuscript. No potential conflict of interest was reported by the author(s).

IRB approved

Reviewed and approved by UCLA IRB (#17-001267).

Additional information

Funding

Statistical analyses for this research was supported by NIH National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant no. UL1TR001881.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.